GALT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.0M
-2.3%
4.1M
+21.2%
3.4M
-19.8%
4.2M
-9.2%
4.6M
R&D
2.1M
-4.3%
2.2M
+15.4%
1.9M
-26.0%
2.6M
-19.9%
3.3M
SG&A
1.8M
+0.1%
1.8M
+28.9%
1.4M
-9.8%
1.6M
+16.3%
1.4M
Operating Income
-3982000
+2.3%
-4077000
-21.2%
-3365000
+19.8%
-4198000
+9.2%
-4625000
EBITDA
-3982000
+2.3%
-4077000
-21.2%
-3365000
+19.8%
-4198000
+9.2%
-4625000
Net Income
-9113000
-80.6%
-5046000
+8.3%
-5500000
+32.8%
-8184000
-8.8%
-7521000
EPS (Basic)
$-0.14
-75.0%
$-0.08
+11.1%
$-0.09
+30.8%
$-0.13
-8.3%
$-0.12
EPS (Diluted)
$-0.14
-75.0%
$-0.08
+11.1%
$-0.09
+30.8%
$-0.13
-8.3%
$-0.12
Shares (Diluted)
65.9M
+0.1%
65.8M
+1.6%
64.8M
+0.9%
64.2M
+1.2%
63.4M
Galectin Therapeutics (GALT) โ€” Financials